Short Interest in Lunai Bioworks Inc. (NASDAQ:LNAI) Decreases By 47.7%

Lunai Bioworks Inc. (NASDAQ:LNAI) saw a significant decrease in short interest in June. As of June 30th, there was short interest totaling 150,195 shares, a decrease of 47.7% from the June 15th total of 287,256 shares. Based on an average daily volume of 4,793,299 shares, the days-to-cover ratio is presently 0.0 days. Currently, 3.3% of the shares of the company are sold short.

Lunai Bioworks Stock Performance

NASDAQ LNAI traded down $0.03 on Wednesday, reaching $2.96. The company’s stock had a trading volume of 7,300 shares, compared to its average volume of 1,657,578. Lunai Bioworks has a twelve month low of $1.21 and a twelve month high of $28.80. The firm’s 50 day moving average is $2.82 and its two-hundred day moving average is $3.98. The stock has a market cap of $13.40 million, a PE ratio of -7.39 and a beta of 0.37.

Lunai Bioworks (NASDAQ:LNAI) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.10) earnings per share (EPS) for the quarter. The firm had revenue of $0.02 million for the quarter.

Analyst Ratings Changes

A number of brokerages recently issued reports on LNAI. Weiss Ratings reiterated a “sell (e+)” rating on shares of Lunai Bioworks in a research report on Wednesday, July 8th. Wall Street Zen raised Lunai Bioworks to a “sell” rating in a report on Saturday, May 23rd. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

Institutional Investors Weigh In On Lunai Bioworks

An institutional investor recently bought a new position in Lunai Bioworks stock. Millennium Management LLC purchased a new stake in Lunai Bioworks Inc. (NASDAQ:LNAI) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 202,629 shares of the company’s stock, valued at approximately $288,000. Millennium Management LLC owned 0.87% of Lunai Bioworks as of its most recent SEC filing. Institutional investors own 71.41% of the company’s stock.

About Lunai Bioworks

Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection.